Journal of AdvancedMedical and Dental Sciences Research

Background: Portal vein thrombosis is seen as a relative reason to avoid transarterial chemoembolization (TACE) in hepatocellular cancer. The aim of our study was to assess the effectiveness of TACE treatment in patients with hepatocellular cancer and portal vein (PV) thrombosis. Material and methods:Patients diagnosed with hepatocellular carcinoma (HCC) who came to our hospital between 2001 and 2007 had clinical, biochemical, and radiological examinations. TACE was carried out in individuals who met the inclusion criteria. Further evaluation was conducted using a series of CT scans of the liver at 1, 3, and 6 months. Estimates were made for tumour response and survival rate. Analyses were conducted to determine the factors influencing survival, both individually and collectively. Results:Among the 70 patients involved in the study, 39 were male (55.7%) and the remaining 31 were female (44.3%). Patients were evaluated for tumour response using imaging at regular intervals and the data was compared with the initial laboratory and imaging features obtained before to therapy. Single-variable analysis was employed to evaluate the effect of the treatments on patient survival. An investigation of survival was conducted using Kaplan-Meier calculations. Conclusion:TACE provides a viable palliative treatment option for HCC. Tumour size in the beginning is a factor that can predict survival on its own.